Pharmacology of CS-747 (prasugrel, LY640315), a Novel, Potent Antiplatelet Agent with in Vivo P2Y₁₂ Receptor Antagonist Activity

ABSTRACT

CS-747 (prasugrel, LY640315) is a member of the thienopyridine class of oral platelet aggregation inhibitors that includes ticlopidine and clopidogrel. A single oral administration of CS-747 produced a dose-related inhibition of platelet aggregation in rats that was approximately 10- and 100-fold more potent than that of clopidogrel and ticlopidine, respectively. The antiaggregatory effect of CS-747 was evident at 30 minutes and lasted until 72 hours after dosing, indicating fast onset and long duration of action. CS-747 showed more potent antithrombotic activity compared with clopidogrel and ticlopidine with the same rank order as the antiaggregatory potencies. Combined administration of CS-747 with aspirin to rats produced substantially greater inhibition of both platelet aggregation and thrombus formation compared with each agent alone. The antiplatelet action of CS-747 is due to irreversible and selective blockade of platelet P2Y₁₂ adenosine diphosphate (ADP) receptors by its active metabolite R-138727. In phase I studies, a single oral dose of CS-747 (30 and 75 mg) produced > 50% inhibition of ADP-induced platelet aggregation, with rapid onset (1 hour) and long duration (> 48 hours) of action. In healthy volunteers, once-daily administration of 10 mg CS-747 for 10 days showed significant cumulative inhibition of platelet aggregation from 2 days after the first dose until at least 2 days after the final dose. Studies conducted to date indicate that CS-747 is a highly effective antiplatelet and antithrombotic agent and is anticipated to be effective in the treatment of atherothrombotic and other ischemic vascular diseases.

CS-747 - prasugrel - LY640315 - R-138727 - R-99224 - platelet aggregation - antiplatelet - antithrombotic - P2Y₁₂ receptor antagonist - ADP

REFERENCES

• 1 Gachet C, Hechler B, Leon C et al.. Activation of ADP receptors and platelet function.  Thromb Haemost. 1997;  78 271-275
• 2 George J N. Platelets.  Lancet. 2000;  355 1531-1539
• 3 Jin J, Daniel J L, Kunapuli S P. Molecular basis for ADP-induced platelet activation. II. The P2Y₁ receptor mediates ADP-induced intracellular calcium mobilization and shape change in platelets.  J Biol Chem. 1998;  273 2030-2034
• 4 Hollopeter G, Jantzen H M, Vincent D et al.. Identification of the platelet ADP receptor targeted by antithrombotic drugs.  Nature. 2001;  409 202-207
• 5 Dorsam R T, Kunapuli S P. Central role of the P2Y₁₂ receptor in platelet activation.  J Clin Invest. 2004;  113 340-345
• 6 McTavish D, Faulds D, Goa K L. Ticlopidine. An updated review of its pharmacology and therapeutic use in platelet-dependent disorders.  Drugs. 1990;  40 238-259
• 7 Jarvis B, Simpson K. Clopidogrel. A review of its use in the prevention of atherothrombosis.  Drugs. 2000;  60 347-377
• 8 A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) . CAPRIE Steering Committee.  Lancet. 1996;  348 1329-1339
• 9 Saltiel E, Ward A. Ticlopidine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in platelet-dependent disease states.  Drugs. 1987;  34 222-262
• 10 Gent M, Blakely J A, Easton J D et al.. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke.  Lancet. 1989;  1 1215-1220
• 11 Page Y, Tardy B, Zeni F et al.. Thrombotic thrombocytopenic purpura related to ticlopidine.  Lancet. 1991;  337 774-776
• 12 Steinhubl S R, Tan W A, Foody J M et al.. Incidence and clinical course of thrombotic thrombocytopenic purpura due to ticlopidine following coronary stenting.  JAMA. 1999;  281 806-810
• 13 Bennett C L, Connors J M, Carwile J M et al.. Thrombotic thrombocytopenic purpura associated with clopidogrel.  N Engl J Med. 2000;  342 1773-1777
• 14 Zakarija A, Bandarenko N, Pandey D K et al.. Clopidogrel-associated TTP: an update of pharmacovigilance efforts conducted by independent researchers, pharmaceutical suppliers, and the Food and Drug Administration.  Stroke. 2004;  35 533-537
• 15 Jaremo P, Lindahl T L, Gransson S B et al.. Individual variations of platelet inhibition after loading doses of clopidogrel.  J Intern Med. 2002;  252 233-238
• 16 Muller I, Besta F, Schulz C et al.. Prevalence of clopidogrel nonresponders among patients with stable angina pectoris scheduled for elective coronary stent placement.  Thromb Haemost. 2003;  89 783-787
• 17 Lau W C, Waskell L A, Watkins P B et al.. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction.  Circulation. 2003;  107 32-37
• 18 Lau W C, Gurbel P A, Watkins P B et al.. Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance.  Circulation. 2004;  109 166-171
• 19 Clarke T A, Waskell L A. The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin.  Drug Metab Dispos. 2003;  31 53-59
• 20 Mitsios J V, Papathanasiou A I, Rodis F I et al.. Atorvastatin does not affect the antiplatelet potency of clopidogrel when it is administered concomitantly for 5 weeks in patients with acute coronary syndromes.  Circulation. 2004;  109 1335-1338
• 21 Sugidachi A, Asai F, Ogawa T, Inoue T, Koike H. The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties.  Br J Pharmacol. 2000;  129 1439-1446
• 22 Sugidachi A, Asai F, Yoneda K et al.. Antiplatelet action of R-99224, an active metabolite of a novel thienopyridine-type G(i)-linked P2T antagonist, CS-747.  Br J Pharmacol. 2001;  132 47-54
• 23 Hirota T, Sugii H, Asai F et al.. Efficacy of CS-747, a new potent antiplatelet agent.  Clin Pharmacol Ther. 1999;  65 148
• 24 Quinn M J, Fitzgerald D J. Ticlopidine and clopidogrel.  Circulation. 1999;  100 1667-1672
• 25 Di Minno G, Cerbone A M, Mattioli P L et al.. Functionally thrombasthenic state in normal platelets following the administration of ticlopidine.  J Clin Invest. 1985;  75 328-338
• 26 Coukell A J, Markham A. Clopidogrel.  Drugs. 1997;  54 745-750
• 27 Cattaneo M, Winocour P D, Somers D A et al.. Effect of ticlopidine on platelet aggregation, adherence to damaged vessels, thrombus formation and platelet survival.  Thromb Res. 1985;  37 29-43
• 28 Jackson C W, Steward S A, Ashmun R A, McDonald T P. Megakaryocytopoiesis and platelet production are stimulated during late pregnancy and early postpartum in the rat.  Blood. 1992;  79 1672-1678
• 29 Savi P, Pereillo J M, Uzabiaga M F et al.. Identification and biological activity of the active metabolite of clopidogrel.  Thromb Haemost. 2000;  84 891-896
• 30 Ding Z, Kim S, Dorsam R T, Jin J, Kunapuli S P. Inactivation of the human P2Y₁₂ receptor by thiol reagents requires interaction with both extracellular cysteine residues, Cys17 and Cys270.  Blood. 2003;  101 3908-3914
• 31 Jackson S P, Schoenwaelder S M. Antiplatelet therapy: In search of the ‘magic bullet.’  Nat Rev Drug Discov. 2003;  2 775-789
• 32 Umetsu T, Sanai K. Effect of 1-methyl-2-mercapto-5-(3-pyridyl)-imidazole (KC-6141), an anti-aggregating compound, on experimental thrombosis in rats.  Thromb Haemost. 1978;  39 74-83
• 33 Sugidachi A, Asai F, Koike H. In vivo pharmacology of aprosulate, a new synthetic polyanion with anticoagulant activity.  Thromb Res. 1993;  69 71-80
• 34 Asai F, Niitsu Y, Ogawa T et al.. Effects of CS-747, a novel P2Y₁₂ receptor antagonist, on cerebral and peripheral arterial occlusive diseases in rats.  J Thromb Haemost. 2003(suppl);  2033 (abst)
• 35 Dejana E, Callioni A, Quintana A, De Gaetano G. Bleeding time in laboratory animals. II-A comparison of different assay conditions in rats.  Thromb Res. 1979;  15 191-197
• 36 Peters R J, Mehta S R, Fox K A et al.. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the clopidogrel in unstable angina to prevent recurrent events (CURE) study.  Circulation. 2003;  108 1682-1687
• 37 Sugidachi A, Ogawa T, Isobe T et al.. Antiplatelet and antithrombotic effects of CS-747, a novel P2Y₁₂ receptor antagonist, in combination with aspirin.  J Thromb Haemost. 2003(suppl);  2032(abst)
• 38 Jakubowski J, Ogawa T, Sugidachi A et al.. Stereoselective inhibition of human platelet aggregation by R-138727, the active metabolite of CS-747, a novel P2Y₁₂ receptor antagonist.  J Thromb Haemost. 2003(suppl);  2056(abst)
• 39 Gachet C. ADP receptors of platelets and their inhibition.  Thromb Haemost. 2001;  86 222-232
• 40 Kunapuli S P. Multiple P2 receptor subtypes on platelets: a new interpretation of their function.  Trends Pharmacol Sci. 1998;  19 391-394
• 41 Kunapuli S P. Functional characterization of platelet ADP receptors.  Platelets. 1998;  9 343-351
• 42 Kunapuli S P, Daniel J L. P2 receptor subtypes in the cardiovascular system.  Biochem J. 1998;  336 513-523
• 43 Daniel J L, Dangelmaier C, Jin J et al.. Molecular basis for ADP-induced platelet activation. I. Evidence for three distinct ADP receptors on human platelets.  J Biol Chem. 1998;  273 2024-2029
• 44 Boyer J L, Romero-Avila T, Schachter J B, Harden T K. Identification of competitive antagonists of the P2Y₁ receptor.  Mol Pharmacol. 1996;  50 1323-1329
• 45 Vorchheimer D A, Badimon J J, Fuster V. Platelet glycoprotein IIb/IIIa receptor antagonists in cardiovascular disease.  JAMA. 1999;  281 1407-1414
• 46 Thebault J J, Kieffer G, Lowe G D, Nimmo W S, Cariou R. Repeated-dose pharmacodynamics of clopidogrel in healthy subjects.  Semin Thromb Hemost. 1999;  25(Suppl 2) 9-14